1/9/1
DIALOG(R)File 351:Derwent WPI
(c) 2002 Derwent Info Ltd. All rts. reserv.

013685637
WPI Acc No: 2001-169861/ **200118**
XRAM Acc No: C01-050979
New human N-formyl rec ptor gene, useful for diagnosis and treatm nt of disease
Patent Assignee: BOENISCH H (BOEN-I); BRUESS M (BRUE-I)
Inventor: BOENISCH H; BRUESS M
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
DE 19930512	A1	20010111	DE 1030512	A	19990705	200118	B

Priority Applications (No Type Date): DE 1030512 A 19990705
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
DE 19930512	A1		5	C07K-016/00	

Abstract (Basic): **DE 19930512** A1
NOVELTY - The human N-formyl receptor gene (I), including its 5' and 3' untranslated regions.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(a) transcription factors, RNA polymerases, pharmaceuticals and chemicals that up- or down-regulate expression of (I);
(b) mRNA (II), and its splice variants or isoforms, transcribed from (I);
(c) cDNA derived from (II) or from genes introns;
(d) protein (III) derived, or produced, from (II), cDNA or (I);
(e) antibodies or antisera directed against one or more epitopes of (III) or the entire protein;
(f) systems (including eukaryotic cells, yeast cells, Xenopus Oocytes, Baculovirus systems, and bacterial expression systems) that express native or recombinant (III);
(g) ligand binding studies and screening assays that use the native or recombinant receptor, or cells or membranes that contain it;
(h) transgenic and knockout animals that express the receptor at altered level or not at all;
(i) gene therapy method that involves the receptor or its gene, cDNA or mRNA;
(j) (anti)sense oligonucleotides derived from (I);
(k) diagnosis and treatment of diseases in which the receptor is (in)directly implicated;
(l) development of new (or evaluation of known) pharmaceuticals, compounds, chemicals, and techniques; and
(m) modified versions of the protein, gene, cDNA, and mRNA sequences.
USE - (I), also related nucleic acids, proteins, antibodies, ligands etc., are potentially useful for diagnosis and (gene) therapy of diseases, also for drug screening, identification of ligands and production of transgenic animals.
pp; 5 DwgNo 0/0
Technology Focus:
TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Antibody: The antibody is preferably monoclonal.
Title Terms: NEW; HUMAN; N; FORMYL; RECEPTOR; GENE; USEFUL; DIAGNOSE; TREAT ; DISEASE
Derwent Class: B04; D16
International Patent Class (Main): C07K-016/00
International Patent Class (Additional): C07K-014/005; C07K-014/435
File Segment: CPI
Manual Codes (CPI/A-N): B04-B03C; B04-E02D; B04-E03D; B04-E07; B04-F0100E; B04-F0200E; B04-F0300E; B04-F0900E; B04-F1000E; B04-F1100E; B04-G04; B04-G21; B04-H01; B04-K0100E; B04-L04A; B04-P0100E; B11-C07A; B11-C08E; B12-K04A; B12-K04E; D05-C12; D05-H09; D05-H11A; D05-H12A; D05-H12D2; D05-H12E; D05-H14A1; D05-H14A2; D05-H14A3; D05-H14B4; D05-H17A6
Chemical Fragment Codes (M1):

01 M423 M710 M905 N135 Q233 RA00NS-N
02 M423 M710 M781 M905 N102 N135 P831 Q233 RA00H3-D RA00H3-N
03 M423 M710 M905 N135 Q233 RA012P-N
04 M423 M710 M905 Q233 RA0DQN-N
05 M423 M710 M781 M905 N102 P831 Q233 RA00C8-D RA00C8-N
06 M423 M710 M781 M905 N102 N135 P831 Q233 RA00GT-D RA00GT-N
07 M423 M710 M905 Q233 RA013I-N

Chemical Fragment Codes (M6):

08 M905 P831 Q233 R515 R521 R621 R627 R633

Specific Compound Numbers: RA00NS-N; RA00H3-D; RA00H3-N; RA012P-N; RA0DQN-N ; RA00C8-D; RA00C8-N; RA00GT-D; RA00GT-N; RA013I-N

Key Word Indexing Terms:

01 93605-0-0-0-CL, NEW 184616-0-0-0-CL, NEW 105730-0-0-0-CL, NEW 218588-0-0-0-CL, NEW 184587-0-0-0-CL, NEW 200757-0-0-0-CL, NEW 184610-0-0-0-CL, NEW